Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation
May 16th, 2016
Intravenous administration of endotoxin reliably elicits dose-dependent physiological and immunological alterations consistent with several pathological states. This reductionist approach permits the investigation, modeling and experimental modification of systemic inflammation and its downstream effects in man.
The overall goal of this procedure is to facilitate the investigation, modeling, and experimental modification of systemic inflammation and its downstream effects in humans. This method can help answer many of the key questions that still prevail today about the pathogenesis of critical illnesses. We believe that Intravenous Endotoxin Challenge, and this is many of the vascular, blood, endocrine, immunological, as well as organ-specific changes that mimic those observed in pathological inflammatory states.
The main advantages of this technique are the ability to access and potentially pharmacologically modify both the early and late phases of inflammation, triggered by biologically relevant stimulus. The implications of this technique extend toward the diagnosis and therapy of critical illnesses, such as sepsis, as it partially replicates clinically-observed physiological and immunological alterations. Helping me demonstrate the procedural, Alexander Maini, an experienced clinician, has a minimum of at least one medically qualified investigator is required for the procedure.
On the day of the procedure, use aseptic non-touch technique, to reconstitute a fresh vile of 10, 000 units of clinical center reference endotoxin and five milliliters of sterile water for injection. Then place the vile on a vortex shaker for at least one hour to ensure all of the endotoxin enters into the solution. Next, arrange a bed with the head at 45 degrees in an appropriate location with access to additional clinical assistance and resuscitation equipment, if required, and confirm that the required clinical and experimental equipment are functional.
Before beginning the procedure, confirm that the patient has provided written consent and has previously undergone a health screen, including a clinical history, examination, and core investigations. Ask the participant about any new illnesses or symptoms since undertaking the health screen, and confirm the compliance with the protocol-specific instructions. Ensure the participant has voided the bladder and bowel.
Then, after a weight check, ask the participant to lie on the prepared bed in a comfortable position. Next, using aseptic non-touch technique, insert an intravenous cannula for the administration of the endotoxin, followed by the intravenous placement of a second intravascular line with large bore cannula in the antecubital fossa for the administration of fluids and the ongoing blood draw. After the lines have been inserted, draw and discard five milliliters of blood.
And then obtain a blood sample for baseline tests. Flush the line with 10 milliliters of 0.9 percent sodium chloride, and attach clinical monitoring equipment, as appropriate. Then record the baseline routine clinical observations on an appropriate vital sign chart.
Subjective symptom scoring should additionally be performed to monitor the participant experience. When the participant and endotoxin are ready, draw a weight-adjusted dose of the solution into a one milliliter syringe. Here, two nanograms per kilogram will be administered.
To administer the endotoxin. flush the first cannula with 0.9 percent sodium chloride to ensure that the instrument is correctly cited and patented, and then deliver the endotoxin bolus dose in under two minutes into a three-way tap at the hub of the IV line. It is vital that the endotoxin is administered rapidly and in its entirety, to ensure a consistent interparticipant response.
Please also note that the volunteers will not report some traumatic alterations immediately, with the onset occurring instead at around 60 minutes. After the bolus IV endotoxin has been completely delivered, flush the line with 10 more milliliters of 0.9 percent sodium chloride, to ensure that all of the toxin enters the circulation. Then, monitor the participant for a minimum of eight hours, recording and reviewing the vital signs and any clinical observations at a minimum of once per hour.
Continuous monitoring, such as three lead cardiac monitoring, may also be undertaken. Routinely administer two to three liters of IV crystalloid fluid to the participant over six to eight hours to replace insensible losses and to substitute routine fluid intake, if nil by mouth. Predetermined samples, for instance, of blood or urine, may be obtained at any point following the endotoxin administration.
When all of the participants observations have returned to baseline, or are demonstrating a consistent trend to normal, have the attending clinician confirm that the participant's symptoms have settled and that sensation of the monitoring is permissible. Then remove all of the monitoring equipment and intravascular lines, and discharge the participant. A bolus of two nanograms per kilogram reliantly elicits the features of Systemic Inflammatory Response Syndrome, including a raised core temperature, heart, and respiratory rates and white blood cell count.
These responses are accompanied by the release of humoral mediators of inflammation, including pro-inflammatory cytokines, like tumor necrosis factor alpha, and acute phase proteins, like c-reactive protein. Metabolism, in both the central and peripheral tissues is also altered and multiple organ-specific functional alterations are elicited, including a variety of flu-like symptoms, such as headache, myalgia, and nausea that peak in intensity around one to two hours and largely abate by six hours. The procedure of Intravenous and Endotoxin Challenge can typically be completed in eight hours, depending on the individual volunteer's responses.
While attending this procedure, it's important to remember that the safety of the participant is paramount. This procedure may be adapted with the addition of focus investigations, or with the administration of pharmacologocally active compounds to further understand the specific physiological and immunological parameters of interest. After watching this video, you should have a good understanding of how to safely induce a systemic inflammatory response in humans, via the screening and consenting of healthy humans before and their monitoring after the administration of endotoxin.
Don't forget that endotoxin injection is potentially hazardous and that precautions, including ensuring the availability of resuscitation equipment and additional clinical support, should always be taken while performing this procedure.
Overview
This article details the Intravenous Endotoxin Challenge procedure, which is designed to study systemic inflammation and its effects in humans. The method allows for the investigation of physiological and immunological changes that resemble those seen in critical illnesses.
Key Study Components
Area of Science
- Neuroscience
- Immunology
- Clinical Research
Background
- Systemic inflammation is a critical factor in many diseases.
- The Intravenous Endotoxin Challenge mimics inflammatory responses.
- Understanding these responses can aid in diagnosing and treating critical illnesses.
- Research in this area is essential for advancing clinical practices.
Purpose of Study
- To facilitate the investigation of systemic inflammation.
- To model and modify inflammatory responses experimentally.
- To explore the pathogenesis of critical illnesses like sepsis.
Methods Used
- Intravenous administration of endotoxin.
- Monitoring of physiological and immunological changes.
- Use of aseptic techniques during the procedure.
- Continuous observation of participants for safety.
Main Results
- Endotoxin administration elicits features of Systemic Inflammatory Response Syndrome.
- Physiological changes include increased heart rate and temperature.
- Immunological responses involve the release of pro-inflammatory cytokines.
- Participants experience flu-like symptoms that peak and then subside.
Conclusions
- The procedure is effective for studying systemic inflammation.
- It provides insights into the pathophysiology of critical illnesses.
- Safety protocols are crucial for participant well-being.
Frequently Asked Questions
Executive Industry Relevance
The intravenous endotoxin challenge provides a controlled human model to probe systemic inflammation, enabling mechanistic interrogation of inflammatory pathways relevant to sepsis and critical illness therapeutics. By delivering reproducible physiological and immunological responses, the platform supports target validation and biomarker discovery in a disease-relevant human system. This approach enhances predictive confidence in preclinical-to-clinical translation by de-risking target hypotheses through direct human evidence.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by measuring downstream inflammatory mediators such as TNF-alpha and CRP in response to TLR4 activation.
- Operational Value: Provides a standardized, dose-tunable stimulus (0.06–4 ng/kg) to isolate variables and assess target engagement across a spectrum of inflammatory severity.
- Predictive Value: Supports mechanistic de-risking by linking target modulation to measurable changes in vital signs, leukocyte counts, and cytokine release in healthy humans.
Screening & Assay Development
- Scientific Value: Generates quantitative, time-resolved readouts (e.g., core temperature, heart rate, white blood cell count) suitable for assay standardization and inter-laboratory reproducibility.
- Operational Value: Facilitates preparation of a validated human inflammatory state for screening immunomodulatory compounds pre- or post-challenge.
- Translational Value: Yields pharmacodynamic markers that reflect pathway activity, enabling dose-response modeling and target selectivity assessment.
Translational & Preclinical Research
- Scientific Value: Bridges preclinical findings to human biology by replicating early-stage sepsis-like physiology, including vascular, endocrine, and organ-specific functional alterations.
- Operational Value: Enables continuous monitoring of physiological parameters over 6–8 hours, supporting kinetic profiling of drug effects on inflammatory cascades.
- Risk-Adjusted Advancement: Informs go/no-go decisions by demonstrating target-mediated modulation of clinically relevant inflammatory phenotypes.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through preclinical validation, offering a human-relevant bridge to assess target modulation before costly clinical trials.
- Discovery Biology: Supports hypothesis testing by enabling controlled induction of systemic inflammation to clarify pathway involvement and target function.
- Screening: Delivers assay-ready biological systems with standardized inflammatory responses for reliable compound evaluation.
- Analytics: Provides multimodal readouts (vital signs, hematological, immunological) that allow comparative analysis across conditions and interventions.
- Translational Research: Connects early discovery to preclinical continuity through measurable, clinically analogous physiological changes.
- Enterprise Reuse: Establishes a reusable platform for iterative testing of anti-inflammatory agents across multiple projects and therapeutic areas.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity through direct human evidence of target-pathway relationships.
- Operational Value: Ensures reproducibility via standardized endotoxin dosing, aseptic technique, and protocolized monitoring intervals.
- Strategic Value: Improves capital efficiency by enabling early de-risking of targets, reducing late-stage failure due to lack of target validation in humans.
- Portfolio Impact: Supports risk-adjusted prioritization by generating human data on target modulation that informs advancement decisions.
Implementation Considerations
- Requires medically qualified investigators and clinical staff trained in endotoxin handling and emergency response.
- Dependent on access to clinical-grade endotoxin (CCRE), infusion equipment, and real-time monitoring capabilities (vital signs, cardiac).
- Necessitates standardized training for symptom scoring, blood sampling, and fluid management across study sites.
- Involves participant screening for exclusion criteria and compliance with pre-protocol instructions (fasting, voiding).
- Limited to studying acute inflammatory responses; not suitable for modeling chronic inflammation or adaptive immune processes without protocol modification.
